Log in

Novo Nordisk A/S Stock Price, News & Analysis (NYSE:NVO)

$52.47
+0.44 (+0.85 %)
(As of 10/16/2019 03:22 AM ET)
Today's Range
$52.12
Now: $52.47
$52.58
50-Day Range
$49.41
MA: $51.68
$53.39
52-Week Range
$41.59
Now: $52.47
$53.55
Volume625,372 shs
Average Volume1.42 million shs
Market Capitalization$124.25 billion
P/E Ratio20.82
Dividend Yield1.23%
Beta0.58
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.72 billion
Cash Flow$2.82 per share
Book Value$3.24 per share

Profitability

Net Income$5.91 billion

Miscellaneous

Employees43,202
Outstanding Shares2,368,001,000
Market Cap$124.25 billion
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a Semi-Annual dividend on Friday, August 9th. Stockholders of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date of this dividend is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S declared that its board has initiated a share buyback plan on Friday, February 2nd 2018, which authorizes the company to buyback shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings results on Friday, August, 9th. The company reported $0.61 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.61. The company earned $4.52 billion during the quarter, compared to analyst estimates of $4.41 billion. Novo Nordisk A/S had a return on equity of 75.16% and a net margin of 32.16%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Novo Nordisk A/S.

What price target have analysts set for NVO?

15 analysts have issued 12 month target prices for Novo Nordisk A/S's shares. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next twelve months. This suggests a possible upside of 246.1% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

Media headlines about NVO stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a news impact score of -2.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Novo Nordisk A/S.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,490,000 shares, an increase of 12.1% from the August 30th total of 5,790,000 shares. Based on an average daily volume of 1,570,000 shares, the short-interest ratio is currently 4.1 days. Currently, 0.4% of the company's shares are sold short. View Novo Nordisk A/S's Current Options Chain.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), Pfizer (PFE), Celgene (CELG), Johnson & Johnson (JNJ), Netflix (NFLX), AbbVie (ABBV), Alibaba Group (BABA), Cisco Systems (CSCO), Walt Disney (DIS) and Starbucks (SBUX).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.01%), Cim LLC (0.01%), Ferguson Wellman Capital Management Inc. (0.01%), Penbrook Management LLC (0.01%), Smithbridge Asset Management Inc. DE (0.00%) and Atwater Malick LLC (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Crossmark Global Holdings Inc., Baldwin Brothers Inc. MA, Gradient Investments LLC, First Hawaiian Bank, Global Trust Asset Management LLC, Carroll Financial Associates Inc. and Bangor Savings Bank. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Intercontinental Wealth Advisors LLC, Atwater Malick LLC, Cim LLC, Pacer Advisors Inc., Smithbridge Asset Management Inc. DE, TIAA FSB and OmniStar Financial Group Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $52.47.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $124.25 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  414 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Featured Article: NASDAQ

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel